

**Table SI. Patients' characteristics and outcomes**

Patient	Patient 1	Patient 2	Patient 3	Raush et al. (6)	Curry et al. (7)	Ingen-Housz-Oro et al. (8)	Maderal et al. (9)
Sex/age (years) at PCDLBCL diagnosis	F/80	M/78	F/64	M/77	M/74	M/66	M/70
CTCL subtype and stage if MF	MF stage IIIA	SS	SS	MF	SS	SS	MF stage IIIB
MTX maximal weekly dose (mg)	40	22.5	22.5	25 then 15 (after reintroduction)	NA	20	20
Time interval between PCDLBCL occurrence and MTX introduction (months)	10	20	66	36 after first introduction (and 12 after reintroduction)	NA	3	2
PCDLBCL clinical presentation (and site)	Solitary ulcerated nodule (back)	5 ulcerated nodules (scalp)	Multiple ulcerated nodules (right upper limb), axillary infiltration and multiple enlarged lymph nodes	Several ulcerated nodules (left leg)	Solitary ulcerated plaque (right thigh)	Solitary skin tumour (chest) and accentuation of lymph nodes enlargement	Several pink, shiny, eroded papules and nodules on the right frontal scalp, left forehead and left cheek
Association of PCDLBCL with CTCL in skin biopsy	Yes (residual MF)	No	Yes (admixed with SS features)	No	No	Yes (admixed with SS features)	No
EBV presence in skin	Positive	Positive	Negative	Positive	Positive	Positive	Positive
PCDLBCL lesions (ISH and/or IHC)	Yes	Yes	Yes (R-CHOP)	Yes (RTX 4 weekly IV infusions)	Yes	Yes (R-CHOP)	Yes
MTX withdrawal (and additional treatment targeting B cells if applicable)	72, CR	99, CR	17 months, CR	21 months, CR	NA, CR	3 months, CR	6 months, CR
Follow-up duration after MTX withdrawal (months) and PBCDLBC status after MTX withdrawal +/- additional treatment; vital status at last news	No PCDLBCL recurrence	No PCDLBCL recurrence	No PCDLBCL recurrence	No PCDLBCL recurrence despite MTX reintroduction	NA	No PCDLBCL recurrence	No PCDLBCL recurrence
	Deceased (non CTCL)	Still alive with CTCL	Deceased (CTCL)	Deceased (CTCL)	Deceased (CTCL)	Deceased (CTCL)	Still alive with CTCL

CR: complete remission; CTCL: cutaneous T-cell lymphoma; EBV: Epstein-Barr Virus; ECPC: extracorporeal photo chemotherapy; MF: mycosis fungoides; MTX: methotrexate; NA: not available; PCDLBCL: primary cutaneous diffuse large B-cell lymphoma; R-CHOP: rituximab-cyclophosphamide-donorubicin-vincristine-prednisolone; RTX: rituximab; SS: Sézary syndrome.